Related Experiment Video
Updated: May 9, 2025
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
[Research progress on the role of SIRT1 in heart failure]
Yang-Ming Zhang1, Mai Lyu1, Chen-Yang Wu1
1Institute of Cardiovascular Diseases, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
Insights
Novel therapies targeting SIRT1 (an NAD+-dependent deacetylase) show promise for heart failure (HF). This review explores SIRT1
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Aging Research
Background:
- Heart failure (HF) is a significant global health burden with high mortality.
- Current treatments for HF are limited, necessitating novel therapeutic strategies.
- SIRT1, a NAD+-dependent deacetylase, exhibits cardioprotective properties and influences cardiovascular aging.
Purpose of the Study:
- To review the multifaceted roles of SIRT1 in heart failure (HF) pathophysiology.
- To summarize findings on SIRT1 gene expression in cardiac tissues from HF models and patients.
- To assess the therapeutic potential of SIRT1 activators for HF treatment.
Main Methods:
- Literature review of studies on SIRT1 and heart failure.
- Analysis of gene expression data in animal models and human cardiac tissues.
- Examination of ongoing clinical trials involving SIRT1 activators.
Main Results:
- SIRT1 plays a critical role in the molecular mechanisms underlying HF.
- Altered SIRT1 expression is observed in cardiac tissues affected by HF.
- Several clinical trials are investigating SIRT1 activators for HF therapy.
Conclusions:
- SIRT1 and its activators represent a promising therapeutic avenue for heart failure.
- Further research into SIRT1's pathological roles can inform new prevention strategies.
- Targeting SIRT1 may offer novel clinical interventions for cardiovascular aging and HF.
Abstract:
Heart failure (HF) is a common end-stage clinical manifestation of cardiovascular diseases, imposing substantial health-related burdens worldwide. With its high mortality rates and poor long-term prognosis, there is a pressing need for novel therapies. SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, has anti-cardiovascular aging properties and other cardioprotective effects, attracting much research attention in recent years. In addition, SIRT1 plays an important role in HF pathophysiology. This review summarized the roles of SIRT1 and its activators in HF, the changes of SIRT1 gene expression in cardiac tissues from animal models and HF patients, and the current status of clinical trials investigating SIRT1 activators as potential therapies for HF. This will provide new ideas for further exploration of pathological mechanisms and the development of clinical prevention strategies for HF.
More Related Videos
10:18Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
Published on: February 1, 2022
11:38Assessment of Cardiac Function and Energetics in Isolated Mouse Hearts Using 31P NMR Spectroscopy
Published on: August 31, 2010
